These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21098689)

  • 1. D-penicillamine interferes with S-homocysteinylation and S-cysteinylation of LDL apolipoprotein B.
    Sotgia S; Carru C; Pinna GA; Deiana L; Zinellu A
    J Clin Pharmacol; 2011 Dec; 51(12):1728-32. PubMed ID: 21098689
    [No Abstract]   [Full Text] [Related]  

  • 2. The metabolism and pharmacology of D-penicillamine in man.
    Perrett D
    J Rheumatol Suppl; 1981; 7():41-50. PubMed ID: 7014876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of the therapeutic use of D-penicillamine.
    Walshe JM
    J Rheumatol Suppl; 1981; 7():3-8. PubMed ID: 7014875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies with 35S-labelled DL-penicillamine in patients with Wilson's disease.
    Gibbs K; Walshe JM
    Q J Med; 1971 Apr; 40(158):275-87. PubMed ID: 5091812
    [No Abstract]   [Full Text] [Related]  

  • 5. [On hepatolenticular degeneration (Wilson's disease). 3. Hepatic localization of Cu64: scintigraphic and dynamic study before and after treatment with BAL and D-penicillamine].
    D'Addabbo A; Damato VD; Germinario L; Campanella G; Boccuni N
    Acta Neurol (Napoli); 1971; 26(4):436-48. PubMed ID: 5132825
    [No Abstract]   [Full Text] [Related]  

  • 6. [Laboratory changes and complications during long-term therapy of Wilson's disease using D-penicillamine].
    Hauftová D; Slavícek J; Hartl J; Seidlová V; Komenda S
    Vnitr Lek; 1970 Apr; 16(4):344-53. PubMed ID: 5443326
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Wilson's disease (hepatolenticular degeneration) with penicillamine and low-copper diet.
    Goldstein NP; Tauxe WN; McCall JT; Gross JB; Randall RV
    Trans Am Neurol Assoc; 1969; 94():34-7. PubMed ID: 5374484
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma D-penicillamine redox state evaluation by capillary electrophoresis with laser-induced fluorescence.
    Zinellu A; Carru C; Sotgia S; Deiana L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 803(2):299-304. PubMed ID: 15063339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatolenticular degeneration treated by Cuprenil Polfa (d-penicillamine)].
    Hasik J; Kozal H
    Pol Tyg Lek; 1975 Aug 4-11; 30(31-32):1329-30. PubMed ID: 1161576
    [No Abstract]   [Full Text] [Related]  

  • 10. Brief observations on the management of Wilson's disease.
    Walshe JM
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):1-3. PubMed ID: 122651
    [No Abstract]   [Full Text] [Related]  

  • 11. [On hepatolenticular degeneration (Wilson's disease). II. Treatment of 2 cases of Wilson's disease for 8 months with D-penicillamine].
    Germinario L; Campanella G; D'Addabbo A
    Acta Neurol (Napoli); 1971; 26(4):423-35. PubMed ID: 5132824
    [No Abstract]   [Full Text] [Related]  

  • 12. [Acute hemolytic anemia associated with D-penicillamine absorption deficiency in Wilson's disease].
    Ramírez Sánchez MJ; Calvo Villas JM; Sicilia Guillén FJ; Salah S
    Rev Clin Esp; 1999 Feb; 199(2):117-8. PubMed ID: 10216413
    [No Abstract]   [Full Text] [Related]  

  • 13. Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease.
    Falkmer S; Samuelson G; Sjölin S
    Pediatrics; 1970 Feb; 45(2):260-8. PubMed ID: 5413388
    [No Abstract]   [Full Text] [Related]  

  • 14. [Westphal-Strumpell disease. Description of a clinical case].
    Nuccetelli F; Assetta M; Colangelo U; Gambi D
    Minerva Med; 1987 Sep; 78(17):1321-3. PubMed ID: 3670684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for assaying D-penicillamine in a clinical setting.
    Crawhall JC
    Clin Invest Med; 1984; 7(1):31-4. PubMed ID: 6723121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Penicillamine in the treatment of scleroderma. Lathyrogenic drugs].
    Szczepanski A
    Przegl Dermatol; 1971; 58(3):355-9. PubMed ID: 4944035
    [No Abstract]   [Full Text] [Related]  

  • 17. Piggy-back race.
    Lock EA
    Hum Exp Toxicol; 1995 Nov; 14(11):931-2. PubMed ID: 8588958
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Wilson's disease.
    Brewer GJ; Yuzbasiyan-Gurkan V; Young AB
    Semin Neurol; 1987 Jun; 7(2):209-20. PubMed ID: 3332455
    [No Abstract]   [Full Text] [Related]  

  • 19. [The therapeutic use of D-penicyllamine in the light of most recent pharmacokinetic and clinical observations (author's transl)].
    Sarosiek J; Rudy J
    Przegl Lek; 1979; 36(3):337-41. PubMed ID: 451263
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on D-penicillamine metabolism in cystinuria and rheumatoid arthritis: isolation of S-methyl-D-penicillamine.
    Perrett D; Sneddon W; Stephens AD
    Biochem Pharmacol; 1976 Feb; 25(3):259-64. PubMed ID: 1267823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.